Figure 6.

Cumulative incidence of second malignancies accounting for death as a competing risk. (A) Cumulative incidence of any second malignancy by treatment arm. (B) Cumulative incidence of secondary leukemia and myelodysplastic syndrome by treatment arm. (C) Cumulative incidence of any second malignancy by radiotherapy group (radiotherapy was recommended in case of partial remission including residual lesions of at least 2.5 cm in the largest diameter and a positive PET after chemotherapy). BEACOPP-14 = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in dose-dense variant, CIF = cumulative incidence function, eBEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated dose, MDS = myelodysplastic syndrome, sHR = subdistribution hazard ratio.